Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 364,152
  • Shares Outstanding, K 97,628
  • Annual Sales, $ 30,480 K
  • Annual Income, $ -96,970 K
  • 60-Month Beta 1.72
  • Price/Sales 11.91
  • Price/Cash Flow N/A
  • Price/Book 4.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.32
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +19.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.48 +7.18%
on 03/19/19
4.14 -9.90%
on 04/12/19
+0.21 (+5.97%)
since 03/18/19
3-Month
3.02 +23.51%
on 03/13/19
5.11 -27.01%
on 01/25/19
-1.36 (-26.72%)
since 01/18/19
52-Week
3.02 +23.51%
on 03/13/19
6.30 -40.79%
on 10/02/18
-1.17 (-23.88%)
since 04/18/18

Most Recent Stories

More News
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress...

INO : 3.73 (+0.27%)
New Research: Key Drivers of Growth for Zillow Group, Genpact, Royal Caribbean Cruises, CommScope Holding, Inovio Pharmaceuticals, and E.W. Scripps -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Zillow Group, Inc. (NASDAQ:Z), Genpact...

SSP : 22.60 (-1.91%)
COMM : 26.01 (-1.55%)
G : 35.98 (+0.25%)
Z : 36.28 (-1.89%)
RCL : 120.99 (-1.83%)
INO : 3.73 (+0.27%)
ZG : 35.61 (-2.01%)
Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 3.73 (+0.27%)
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

PDLI : 3.58 (+3.47%)
AZN : 38.80 (+0.08%)
INO : 3.73 (+0.27%)
KMDA : 6.17 (-1.44%)
Biotech Brief: Growing Number of Ongoing Clinical Trials for Leukemia (AML) Brings New Hope

In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or...

CHRS : 14.71 (-0.20%)
CVM : 5.95 (+2.94%)
INO : 3.73 (+0.27%)
INSM : 29.84 (+1.29%)
MBRX : 1.11 (+14.08%)
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457...

INO : 3.73 (+0.27%)
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

AZN : 38.80 (+0.08%)
INO : 3.73 (+0.27%)
RHHBY : 32.6900 (-0.09%)
REGN : 333.34 (-2.81%)
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent...

INO : 3.73 (+0.27%)
Inovio Closes Enrollment in Brain Cancer Study Before Time

Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

INO : 3.73 (+0.27%)
RHHBY : 32.6900 (-0.09%)
REGN : 333.34 (-2.81%)
SNY : 41.31 (+0.54%)
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs(TM)) generated potent anti-tumor activities in a preclinical study. Results...

INO : 3.73 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade INO with:

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 3.89
1st Resistance Point 3.81
Last Price 3.73
1st Support Level 3.63
2nd Support Level 3.53

See More

52-Week High 6.30
Fibonacci 61.8% 5.05
Fibonacci 50% 4.66
Fibonacci 38.2% 4.27
Last Price 3.73
52-Week Low 3.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar